CancerDrs

Breast Cancer clinical trials in Tennessee

48 actively recruiting breast cancer trials at 8 sites across Tennessee.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full breast cancer transparency page →

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Tennessee:
  • Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
  • The West Clinic - Wolf River — Germantown, Tennessee
  • Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…

Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Tennessee:
  • University of Tennessee - Knoxville — Knoxville, Tennessee
  • The Children's Hospital at TriStar Centennial — Nashville, Tennessee
  • Vanderbilt Breast Center at One Hundred Oaks — Nashville, Tennessee
  • Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Tennessee:
  • Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
  • University of Tennessee - Knoxville — Knoxville, Tennessee
  • Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Tennessee:
  • Vanderbilt Breast Center at One Hundred Oaks — Nashville, Tennessee
  • Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…

Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Tennessee:
  • Ballad Health Cancer Care - Kingsport — Kingsport, Tennessee
  • Center for Biomedical Research, LLC — Knoxville, Tennessee
  • University of Tennessee — Knoxville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…

Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Tennessee:
  • Baptist Cancer Center — Memphis, Tennessee
  • SCRI Oncology Partners — Nashville, Tennessee
  • Tennessee Oncology, PLLC — Nashville, Tennessee
  • Henry - Joyce Cancer Clinic — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Sites in Tennessee:
  • Sarah Cannon Research Institute — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…

Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Tennessee:
  • Research Site — Chattanooga, Tennessee
  • Research Site — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Tennessee:
  • West Cancer Center — Germantown, Tennessee
  • SCRI Oncology Partners — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Tennessee:
  • Tennessee Cancer Specialists ( Site 7001) — Knoxville, Tennessee
  • SCRI Oncology Partners ( Site 7005) — Nashville, Tennessee
  • Nashville General Hospital ( Site 0017) — Nashville, Tennessee
  • Vanderbilt-Ingram Cancer Center ( Site 0038) — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Tennessee:
  • West Cancer Center — Germantown, Tennessee
  • Vanderbilt University Medical Center — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…

Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Tennessee:
  • Tennessee Cancer Specialists — Knoxville, Tennessee
  • SCRI Oncology Partners — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in Tennessee:
  • Sarah Cannon Research Institute — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Tennessee:
  • Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
  • Regional Cancer Center at Johnson City Medical Center — Johnson City, Tennessee
  • Ballad Health Cancer Care - Kingsport — Kingsport, Tennessee
  • Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
  • Vanderbilt Breast Center at One Hundred Oaks — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …

Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Tennessee:
  • Tennessee Oncology, Greco-Hainsworth Center for Research — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT07102381
Sites in Tennessee:
  • Sarah Cannon Research Institute (Nashville) — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…

Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Tennessee:
  • Baptist Cancer Center - Memphis — Memphis, Tennessee
  • SCRI Oncology Partners — Nashville, Tennessee
  • Tennessee Oncology, Pllc — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other…

Sponsor: Pfizer
NCT ID: NCT04606446
Sites in Tennessee:
  • SCRI Oncology Partners — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, seven …

Sponsor: Hoffmann-La Roche
NCT ID: NCT03424005
Sites in Tennessee:
  • Tennessee Oncology - Chattanooga Oncology & Hematology Associates — Chattanooga, Tennessee
  • The West Clinic — Germantown, Tennessee
  • Tennessee Oncology PLLC — Nashville, Tennessee
  • Vanderbilt University Medical Center — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-…

Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT06998407
Sites in Tennessee:
  • Avenzo Therapeutics Recruiting Site — Nashville, Tennessee
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatmen…

Sponsor: Hoffmann-La Roche
NCT ID: NCT04802759
Sites in Tennessee:
  • West Cancer Center — Germantown, Tennessee
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Tennessee:
  • Local Institution - 0063 — Nashville, Tennessee
  • Vanderbilt University Medical Center — Nashville, Tennessee
View on ClinicalTrials.gov →

Showing 25 of 48 trials with sites in Tennessee. See all breast cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-17